Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris
Shuai Shao, … , Paul W. Harms, Johann E. Gudjonsson
Shuai Shao, … , Paul W. Harms, Johann E. Gudjonsson
Published September 7, 2021
Citation Information: JCI Insight. 2021;6(20):e151911. https://doi.org/10.1172/jci.insight.151911.
View: Text | PDF
Research Article Dermatology Immunology

Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris

  • Text
  • PDF
Abstract

Altered epidermal differentiation along with increased keratinocyte proliferation is a characteristic feature of psoriasis and pityriasis rubra pilaris (PRP). However, despite this large degree of overlapping clinical and histologic features, the molecular signatures these skin disorders share are unknown. Using global transcriptomic profiling, we demonstrate that plaque psoriasis and PRP skin lesions have high overlap, with all differentially expressed genes in PRP relative to normal skin having complete overlap with those in psoriasis. The major common pathway shared between psoriasis and PRP involves the phospholipases PLA2G2F, PLA2G4D, and PLA2G4E, which were found to be primarily expressed in the epidermis. Gene silencing each of the 3 PLA2s led to reduction in immune responses and epidermal thickness both in vitro and in vivo in a mouse model of psoriasis, establishing their proinflammatory roles. Lipidomic analyses demonstrated that PLA2s affect mobilization of a phospholipid-eicosanoid pool, which is altered in psoriatic lesions and functions to promote immune responses in keratinocytes. Taken together, our results highlight the important role of PLA2s as regulators of epidermal barrier homeostasis and inflammation, identify PLA2s as a shared pathogenic mechanism between PRP and psoriasis, and as potential therapeutic targets for both diseases.

Authors

Shuai Shao, Jiaoling Chen, William R. Swindell, Lam C. Tsoi, Xianying Xing, Feiyang Ma, Ranjitha Uppala, Mrinal K. Sarkar, Olesya Plazyo, Allison C. Billi, Rachael Wasikowski, Kathleen M. Smith, Prisca Honore, Victoria E. Scott, Emanual Maverakis, J. Michelle Kahlenberg, Gang Wang, Nicole L. Ward, Paul W. Harms, Johann E. Gudjonsson

×

Figure 1

DEGs are overlapped between PRP and psoriatic lesions.

Options: View larger image (or click on image) Download as PowerPoint
DEGs are overlapped between PRP and psoriatic lesions.
(A) Number of gen...
(A) Number of genes significantly regulated in skin lesions of psoriasis (PP) and PRP patients demonstrating complete overlap of PRP genes with those of psoriasis. (B) Enriched Biologic Process GO terms for genes regulated consistently in psoriasis and PRP. (C) The metabonomics biomarker-enzyme network shared between PRP and psoriasis. DEGs, differentially expressed genes.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts